Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 6/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.37 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16062799 | 0.89 | NT5E (0.39) | SELPNT5EMCHR1SSTR2SSTR3 | |
| SCHEMBL16062805 | 0.88 | NT5E (0.36) | LGALS8SELPLGALS3NT5ESSTR2 | |
| SCHEMBL21537963 | 0.87 | SELP (0.43) | LGALS8SELPLGALS3LGALS9LGALS1 | |
| SCHEMBL16849996 | 0.87 | LMNA (0.40) | LGALS8SELPNT5EMCHR1SSTR2 | |
| SCHEMBL16062803 | 0.85 | NT5E (0.36) | LGALS8SELPLGALS3NT5EMCHR1 | |
| SCHEMBL16062798 | 0.85 | LGALS8 (0.45) | LGALS8SELPMCHR1SSTR2SSTR3 | |
| SCHEMBL16062804 | 0.85 | NT5E (0.38) | SELPNT5EMCHR1SSTR2SSTR3 | |
| SCHEMBL16062808 | 0.84 | CD209 (0.42) | LGALS8SELPLGALS3LGALS9LGALS1 | |
| SCHEMBL16062802 | 0.83 | SELP (0.38) | SELPNT5EMCHR1SSTR2SSTR3 | |
| SCHEMBL26443696 | 0.82 | MEN1 (0.41) | SELPLGALS3LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002365-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9493498-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2015-06-25 | — | — | US | disclosed |
| US-8835614-B2 | Oligosaccharide-protein conjugates | GENZYME CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | GENZYME CORPORATION | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300120-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | LGALS8 404/4885SELP 1706/4885LGALS3 615/4885 |
| US-20150175643-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | LGALS8 404/4885SELP 1706/4885LGALS3 615/4885 |
| US-20180002365-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES | MAN2B1, GAA, GBA1 | LGALS8 404/4885SELP 1706/4885LGALS3 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.